InveniAI® Corporation has expanded its flagship AI- and ML-driven innovation monitoring platform, AlphaMeld™ to include products for pharmaceutical drug discovery and development stakeholders.
TargetMeld™ and RxMeld™ will be launched at the upcoming Bio-Europe 2019 Conference set for Nov. 11-12 in Hamburg, Germany.
“The functionality of AlphaMeld and its suite of products continues to advance at a rapid pace, bringing both power and scale to decision-making,” said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI Corporation. more